February 2023 - TinyGems

MondayFeb 27, 2023 10:30 am

Lexaria Bioscience Corp.’s (NASDAQ: LEXX) Additional HYPER-H21-4 Study Findings Offer Better Understanding of the Anti-Hypertensive Effects of DehydraTECH-CBD

Dosing for Lexaria’s ambitious and most comprehensive clinical study, HYPER-H21-4, was successfully completed in July 2022, with newly analyzed results now emerging Its latest findings bring the company closer to its upcoming FDA Phase 1b study while also explaining the patented DehydraTECH-(TM)-processed CBD interaction with the sympatho-chromaffin system via catestatin modulation Lexaria’s management is optimistic that DehyraTECH-CBD and its effectiveness in modulating catestatin levels could become a significant value enhancer should it eventually enter the marketplace as an approved hypertension treatment Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, kicked off its human clinical study, HYPER-H21-1 in…

MondayFeb 27, 2023 9:00 am

Freight Technologies Inc. (NASDAQ: FRGT) Jumps Revenue Guidance for 2023 Amid New Optimism for Commercial Truck Transport, Tracking Tools

B2B marketplace builder Freight Technologies Inc. is an innovator in resources for strengthening commercial supply chain transports between the United States, Canada and Mexico Freight Technologies, also known as Fr8Tech, has developed its AI-powered Fr8App resource to provide shippers and carriers with the tools they need for monitoring shipments and vehicle performance, and improving efficiency In this month’s State of the Union address, President Joe Biden restated his administration’s commitment to boosting manufacturing close to home through policies that sustain price competitiveness and respect for quality employment Amid optimism for U.S. trade and labor policies, Fr8Tech recently announced revenue projections…

ThursdayFeb 23, 2023 9:45 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Looking Forward to 2023 Goals for Patented DehydraTECH(TM) Technology

Lexaria’s 2022 R&D efforts saw high levels of success, establishing the company as one of the world’s leaders in the investigation of CBD for controlling human blood pressure and, separately, demonstrating performance enhancements compared to one of the world's leading anti-seizure medications During Q1 2023, Lexaria expects to provide additional results from its hypertension study HYPER-H21-4; complete dosing in the company’s animal dementia and diabetes studies; complete dosing in the human nicotine study NIC-H21-1; and submit and publish additional results in research journals Lexaria’s DehydraTECH technology currently has 28 granted patents, with many more pending patents in countries worldwide Lexaria…

ThursdayFeb 23, 2023 9:00 am

USMCA Developed to Bolster North American Export Services, with Freight Technologies Inc. (NASDAQ: FRGT) to Capitalize on It

Export services under NAFTA, mainly covering transportation, travel, business, and financial services, increased from $14.7 billion in 1999 to $30.4 billion in 2021 With the transition from NAFTA to USMCA, trade in goods and services is set to see a spike from 2022 going forward, and Fr8Tech expects to capitalize on this Freight Technologies Inc., with its superior freight platform for North American cross-border shipping, yielded a 45% YOY revenue growth for Q2 2022, which it looks to surpass in the subsequent quarters of the current financial year With trucks moving about 70% of North American surface trade by value,…

TuesdayFeb 21, 2023 9:45 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Continues to Foster New Partnerships with its Expanding DehydraTECH(TM) Licensing Opportunities

Lexaria’s patented DehydraTECH(TM) technology improves how APIs enter the bloodstream through the promotion of healthier oral ingestion methods while also increasing the effectiveness of fat-soluble active molecules As a disruptive technology, its impact has been felt by other players in its space, leading Lexaria to open its doors to partnering with industry experts and implementing the technology across many fields, including licensing the technology to Fortune 100 companies Lexaria will continue to make its technology accessible, improving the lives of people around the world Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, has, since 2016, repeatedly demonstrated…

FridayFeb 17, 2023 10:30 am

Freight Technologies Inc. (NASDAQ: FRGT), Providing Efficient Transport, Logistics Support Systems to Boost Continuous Growth of Trade in the USMCA Region

Freight Technologies (“Fr8Tech”) is a North American transportation logistics technology company streamlining and simplifying the once complex process of over-the-road (“OTR”) shipping Through its AI-powered Fr8app B2B marketplace, Fr8Tech connects shippers with carriers, helping reduce waste and inefficiency, and promoting security and visibility The company’s system is handy at a time when trade among parties to the USMCA is on an uptrend The continuous growth of trade among Canada, Mexico, and the United States, depends on the efficiency of trade support structures, such as the logistics-oriented technologies and services Fr8Tech is providing In the years since the North American Free…

FridayFeb 10, 2023 9:00 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Expecting Additional Growth in 2023, Including IND Filing and IND Clinical Study

In addition to a recently released shareholder update letter from the company’s CEO, Chris Bunka, Lexaria Bioscience has now released a new investor presentation Despite 2022 inflationary conditions, Lexaria has seen growth company-wide – including hitting annual budgets +/- 2% over the last two years Lexaria’s patented DehydraTECH(TM) technology offers more effective delivery of active pharmaceutical ingredients into the bloodstream and brain tissue with 28 patents granted and roughly 50 patent applications pending worldwide For Q1 2023, Lexaria expects additional results from its hypertension study HYPER-H21-4, dosing completion in its animal dementia study and diabetes study, dosing completion in human…

ThursdayFeb 09, 2023 10:30 am

Nemaura Medical, Inc. (NASDAQ: NMRD) Featured in Coverage of The MicroCap Rodeo’s 3rd Annual Winter Wonderful and Best Ideas Investor Conference

Nemaura Medical (NASDAQ: NMRD) is a medical technology company developing and commercializing non-invasive wearable diagnostic devices. The company is currently commercializing sugarBEAT(R) and proBEAT(TM). sugarBEAT(R), a CE mark approved Class IIb medical device, is a non-invasive and flexible continuous glucose monitor (“CGM”) providing actionable insights derived from real time glucose measurements and daily glucose trend data, which may help people with diabetes and pre-diabetes to better manage, reverse, and prevent the onset of diabetes. Nemaura has submitted a PMA (Premarket Approval Application) for sugarBEAT(R) to the U.S. FDA. proBEAT(TM) combines non-invasive glucose data processed using artificial intelligence and a digital healthcare…

WednesdayFeb 08, 2023 9:00 pm

Lexaria Bioscience Corp. (NASDAQ: LEXX) – Technology Behind Patented Disruptive DehydraTECH(TM) Drug Delivery Platform

Lexaria has developed the DehydraTECH drug delivery technology, which enhances the performance of multiple categories of fat-soluble active molecules and drugs DehydraTECH has been shown to increase intestinal bioabsorption of certain bioactive compounds by as much as 27 times, with its onset of action being as little as 1.5 minutes The technology is also expected to lower the overall drug costs because it delivers more active molecules to the blood plasma and brain, thus necessitating lower dosing, all while resulting in cost-effective manufacturing DehydraTECH is protected by 28 patents granted worldwide, with approximately 50 more pending Speaking during a late…

MondayFeb 06, 2023 9:00 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) To Intensify Focus on Commercial Execution of its DehydraTECH Technology for the 2023 Calendar year

2022 saw Lexaria introduce its patented DehydraTECH(TM) technology to world-leading collaborators while also exploring DehydraTECH-CBD for the potential treatment of hypertension It also saw success in its research for the potential treatment of conditions such as epilepsy, making the year Lexaria’s most active one yet Significant progress was made on key objectives in 2022, a feat which the company plans to capitalize on and leverage to scale up the commercial execution of its technology in 2023 To facilitate this, Lexaria has brought on board Julian Gangolli, former President of GW Pharmaceuticals USA, as a strategic advisor. Chris Bunka, Lexaria’s CEO,…

Spotlighting undiscovered companies with enormous upside potential.

Contact us: (310) 299-1717

Month: February 2023